aTyr Pharma (ATYR) Form 3 aTYR PHARMA / John T Blake ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Blake John T

(Last) (First) (Middle)

3545 JOHN HOPKINS COURT, SUITE 250

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/28/2015

3. Issuer Name and Ticker or Trading Symbol
aTYR PHARMA INC [ LIFE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Vice President, Finance

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	03/31/2025	Common Stock	12,572	9.15	D
Stock Option (right to buy)	(1)	04/25/2025	Common Stock	8,926	9.15	D
Stock Option (right to buy)	(2)	09/01/2025	Common Stock	10,000	14.08	D
Stock Option (right to buy)	(3)	10/01/2025	Common Stock	2,203	10.24	D

Explanation of Responses:

1. 1/4 of the shares subject to this option shall vest and become exercisable on March 30, 2016, and the remainder shall thereafter vest in 36 equal monthly installments, such that this option is fully exercisable on March 30, 2019. This option is subject to accelerated vesting upon termination without cause upon a change in control of the issuer.

2. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on October 1, 2015, such that this option is fully exercisable on September 1, 2019. This option is subject to accelerated vesting upon termination without cause upon a change of control of the issuer.

3. The shares subject to this option shall begin to vest and become exercisable, if at all, in 48 equal monthly installments upon the achievement of certain performance goals, which must be achieved by October 1, 2017, or such option will be subject to immediate forfeiture. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.

Remarks:

	/s/ John T. Blake	10/30/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.